Scholar Rock Reveals Lean Muscle Preservation Data

Scholar Rock (NASDAQ: SRRK) has announced new preclinical data for SRK-439, a myostatin inhibitor, demonstrating significant lean mass preservation and attenuation of fat mass rebound following the withdrawal of glp-1 receptor agonist (GLP-1 RA) therapy. The company has begun dosing participants in the phase 2 Embraze proof-of-concept trial, evaluating the safety and efficacy of apitegromab, an investigational myostatin inhibitor, in preserving lean muscle mass in individuals living with obesity.

The preclinical research study involved testing SRK-439 in a diet-induced obesity (DIO) mouse model. Mice treated with SRK-439 showed a preservation of lean mass during GLP-1 RA-induced weight loss and a significant increase in lean mass after the discontinuation of GLP-1 RA therapy compared to the control group. Additionally, SRK-439 administration attenuated the fat mass rebound after GLP-1 RA withdrawal, leading to a more favorable body composition in the mice.

The results from the study showed that mice administered with SRK-439 had higher relative lean mass (65.8%) and lower relative fat mass (18.0%) at the end of the withdrawal period compared to the control group (57.1% lean mass and 28.7% fat mass). The absolute lean mass at 8 weeks was significantly higher in the SRK-439 group compared to the control group, with a p-value of less than 0.0001. Similarly, the relative lean mass at 8 weeks also showed a significant difference between the two groups, with a p-value of less than 0.001.

Dr. Mo Qatanani, Chief Scientific Officer at Scholar Rock, emphasized that the preclinical data provide compelling evidence of SRK-439's potential to contribute to healthier weight management and long-term metabolic benefits during and after GLP-1 RA treatment.

The Embraze trial, in which the first participants have been dosed, is a randomized, double-blind, placebo-controlled, phase 2 proof-of-concept trial evaluating the efficacy, safety, and pharmacokinetics of apitegromab in adults with overweight or obesity who are taking a GLP-1 RA. The primary endpoint of the trial is the change from baseline at week 24 in lean mass assessed by dual-energy X-ray absorptiometry.

As a result of these announcements, the company's shares have moved -1.2% on the market, and are now trading at a price of $8.35. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.